The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis

Association between serum uric acid levels and arterial stiffness in patients with psoriasis

This study examined the association between serum uric acid levels (SUA) and arterial stiffness in patients with psoriasis vulgaris. A cross-sectional study was conducted on 205 consecutive patients with psoriasis vulgaris who visited the Dermatology Clinic of China-Japan Friendship Hospital between March 2022 and July 2024. Arterial stiffness was assessed by measuring brachial-ankle pulse wave velocity (baPWV). The patients were divided into four groups (Q1, Q2, Q3, and Q4) according to the quartiles of SUA levels. The clinical data of each group were analysed and compared. Multivariate linear regression was employed to investigate the linear correlation between SUA levels and baPWV, and subgroup analyses were performed. There were differences in sex ratio, body mass index (BMI), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), homocysteine (HCY), and baPWV levels between the four groups. After adjustment for confounders, a significant linear correlation between SUA and baPWV remained, with baPWV increasing by 0.519 cm/s for every 1 mmol/L increase in SUA (β=0.519, 95%CI: 0.176-0.862, P = 0.003). BaPWV was significantly higher in the Q4 group compared with the lowest Q1 group (β=137.043, 95%CI: 43.574-230.511, P = 0.004). Subgroup analysis showed that the positive correlation between SUA and baPWV was more significant in the subgroups of males, moderate-to-severe psoriasis, no history of hypertension, no history of hyperlipidaemia, non-smokers and BMI ≥ 24 kg/m2. In patients with psoriasis, high SUA is associated with increased baPWV. Early screening and intervention of cardiovascular risk should be emphasised. Further studies are needed to establish a causal relationship and to guide treatment.

Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Background

Blood dyscrasias are common in patients with rheumatic diseases, as bone marrow and blood cells can be targets for autoimmune processes. This in addition to the potentially adverse effect of the disease-modifying anti-rheumatic drugs used for the treatment of inflammatory arthritis as in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) on blood counts.

Aim of this study

The aim of this study is to analyze the effect of biologic therapy on complete blood cell parameters, derived ratios, and cell volume indices in Egyptian patients with ankylosing spondylitis and psoriatic arthritis.

Results

One hundred and twenty Egyptian patients had been included, 60 have ankylosing spondylitis (AS) and 60 have psoriatic arthritis (PSA). On comparing the blood indices between the biologics and non-biologics groups of PSA patients, there was a statistically highly significant reduction in red cell distribution width (RDW%) at the biologics group than non-biologics (p < 0.006), where there was a statistically highly significant increase in Hb (hemoglobin)/RDW ratio and Hb/platelets ratio at the biologics group than non-biologics (p < 0.005).

Conclusion

As a result, biologic drugs used in rheumatology practice may have some effects on hematological parameters. In our study, no major negative effects on hematological parameters were observed in patients with AS and PsA who received Secukinumab, Adalimumab-atto, or Golimumab biologic therapy. However, the changes in the hematological indices correlates with their potent anti-inflammatory action in rheumatic patients.

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase the risk of infections, especially respiratory tract infections and candidiasis, and inflammatory bowel disease; the causal relationships are well described. However, evidence regarding the other adverse events is scarce, and causal associations between the adverse events and the biologic remain unresolved. This review aims to present a narrative perspective on the safety of secukinumab and identify some key areas where the safety of secukinumab may potentially be useful in understanding the scope of secukinumab therapy and making informed clinical decisions.

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis

BACKGROUND

Psoriasis is a chronic systemic inflammatory disease, and hyperuricemia is a common comorbidity in patients with psoriasis. However, there are limited reports on the relationship between serum uric acid levels and biological treatment efficacy. The purposes of this study were to compare the differences in serum uric acid levels between patients with psoriasis and healthy controls and analyze the risk of hyperuricemia.

METHODS

A total of 196 patients with psoriasis and 191 age- and sex-matched healthy controls were enrolled in this retrospective cohort study. One hundred and twenty-seven patients with severe psoriasis were treated with biologics. Sixty-eight patients received adalimumab, and 59 patients received secukinumab. Serum uric acid levels were measured at baseline, week 24, and week 48 of treatment.

RESULTS

Patients with psoriasis had higher serum uric acid levels than healthy controls (6.4 ± 1.7 mg/dL vs. 5.7 ± 1.5 mg/dL, P  < 0.001). Hyperuricemia was found in 33.7% (66/196) of patients with psoriasis, which was significantly higher than that in healthy controls (13.1% [25/191], P  < 0.001). Serum uric acid levels and hyperuricemia were not related to the severity of psoriasis ( P  > 0.05). No significant changes in serum uric acid levels and hyperuricemia were observed following adalimumab treatment ( P  > 0.05). The serum uric acid level in patients treated with secukinumab was 6.7 ± 1.6 mg/dL at week 24, which was not statistically different from that at baseline (6.6 ± 1.4 mg/dL, P  = 0.885). Serum uric acid levels were significantly decreased at week 48 (6.3 ± 1.5 mg/dL vs. 6.6 ± 1.4 mg/dL, P  = 0.007) in patients treated with secukinumab. Secukinumab had no significant effect on hyperuricemia either ( P  > 0.05).

CONCLUSIONS

The serum uric acid levels and prevalence of hyperuricemia in patients with psoriasis were significantly higher than those in healthy controls. Secukinumab treatment for 48 weeks successfully decreased serum uric acid levels in patients with psoriasis, whereas adalimumab had no significant effect on serum uric acid levels.

Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications

Psoriatic arthritis (PsA) represents the articular component of the systemic psoriatic disease and the extra-cutaneous disorder most frequently found in patients with psoriasis. Besides the articular involvement, PsA is associated with several metabolic abnormalities such as insulin resistance, hypertension, diabetes and hyperuricemia. Uric acid is the final product of purine metabolism and the etiological substrate of gout. Accumulating evidence highlights the emerging role of hyperuricemia as a major cardiovascular risk factor. Moreover, different studies evaluated the interplay between hyperuricemia and psoriatic disease, suggesting that individuals affected by psoriasis or PsA might present higher serum levels of uric acid and that hyperuricemia might affect severity of clinical manifestations and degree of inflammation in PsA patients. In this review, we focus on the bidirectional relationship between uric acid and PsA, analyzing how uric acid may be involved in the pathogenesis of psoriasis/PsA and how clinical manifestations of PsA and inflammatory mediators are affected by uric acid concentrations. Finally, the effects of anti-rheumatic drugs on uric acid levels and the potential benefit of urate-lowering therapies on psoriasis and PsA were summarized.